The most important number in the microplastics heart study is not 84 percent

The number that travelled around the world in July was 84 percent: the share of severe heart-attack patients in whom researchers detected micro- and nanoplastics, against 40 percent of chronic heart-disease patients and 32 percent of people with clean coronary arteries. The number that did not travel, printed in the same European Society of Cardiology press release, was 12.5 percent - the detection rate among non-smokers living in low-pollution areas. Among patients who both smoked and lived with high air pollution, the rate was 100 percent.

That second pair of figures is the story. It is also the reason the first pair cannot mean what the headlines implied.

What actually happened

The study, published in the *European Heart Journal* and publicised in mid-July 2026, compared blood samples across three cardiac groups and found plastic particles far more often in the sickest. Within 48 hours HealthDay, US News, Fox News, Time and a string of hospital-network sites had the percentages up. Almost all of them cited "a study" without naming the journal or the authors.

That matters less as a citation nicety than as an arithmetic one. Ten outlets carrying the same figure are not ten confirmations. They are one evidentiary origin - a press release - reproduced ten times. Nothing about the story was independently verified between 15 July and the roundups still recirculating it in August.

Why the causal reading is tempting

There is a genuine body of work behind the alarm. Human blood detection was first reported in a small Dutch pilot in 2022. A December 2024 *Scientific Reports* cohort found particles in 88.9 percent of those sampled and reported associations with coagulation and inflammatory markers. A separate 2026 study found particles in nearly all sampled brain tissue, at higher concentrations in tumour tissue than in healthy tissue - which the reporting itself framed as an open question between tumorigenesis and passive accumulation, not an answer. A 2026 systematic review on liver effects assembled mechanistic evidence of harm.

Stacked, these look like a case. Separated, they are three different kinds of claim. Detection studies establish that particles are present. Cross-sectional association studies establish that presence correlates with something. The liver review synthesises animal and organoid toxicology from 2022 to 2025 - biological plausibility, with no human clinical outcomes in it at all. The sense that the field has proven something comes from adding these together, which is not how they add.

The complicating fact

Smoking is one of the best-established causes of myocardial infarction in medicine. Fine particulate air pollution is another. In this cohort, both were strongly associated with having detectable plastics in blood: smokers around six times more likely, PM2.5 exposure independently associated.

So the study compared a group whose defining feature is heart attack with groups whose defining feature is not, and found more plastic in the first - while also reporting that plastic detection tracks the two exposures most likely to have caused the heart attacks. That is textbook confounding, and the authors said so plainly: the findings do not prove that microplastics cause heart attacks. That sentence was in the release. It survived into a minority of the coverage, and into almost none of the headlines.

There is an honest counter-reading, and it deserves stating. Airborne particles from tyre wear, synthetic textiles and combustion are themselves part of ambient particulate pollution. So the smoking-and-pollution gradient can be read two ways: as confounding, or as the dose-response route by which plastics reach the bloodstream in the first place - in which case plastics might be one of the mechanisms through which polluted air damages arteries rather than a bystander. The current data cannot distinguish these. Neither reading appeared in the coverage.

What nobody reported

Two absences shape how much weight the percentages can carry.

First, denominators. None of the searched coverage reports how many patients were in each group. Percentages without sample sizes conceal whether an 84-to-32 gap is a robust signal or a handful of patients either side of a threshold. Second, contamination. Measuring nanoplastics in blood is analytically hard precisely because plastic is everywhere in a laboratory - in tubing, containers, air. Methodologists have flagged background contamination and inter-laboratory detection-limit variability as central problems for this whole field. No outlet in the coverage set raised it. Both remain unknown from the public record rather than resolved.

What can be concluded

That micro- and nanoplastics are getting into human blood, brain and organ tissue is now supported by multiple independent cohorts across four years, and is not seriously in doubt. That their presence correlates with cardiovascular disease is a real finding worth pursuing. That they cause heart attacks is not established by this study, was not claimed by its authors, and is made harder to claim by the study's own exposure data.

The most defensible current reading is narrower and more useful: plastic particles in blood look, on this evidence, like a marker of inhaled particulate exposure - the same exposure that already explains much of the cardiac risk. Whether they add risk of their own is the question the next study has to be designed to answer, and cross-sectional detection work cannot.

Four years after the first human blood detection, the field has produced an impressive quantity of evidence that plastics are in us and almost none that measures what they do once there. The coverage has scaled the alarm faster than the science has scaled the answer.